LL-37 plus stem cells speeds diabetic wound closure in mice

The wire

1. 01In a diabetic mouse wound model, LL-37 combined with adipose-derived stem cells healed wounds faster than either treatment alone, with LL-37 raising stem cell viability dose-dependently.
2. 02Human diabetic wound samples showed deficiency of cathelicidin (CAMP), the LL-37 precursor, offering a rationale readers tracking LL-37 can weigh against gray-market wound-healing claims.
3. 03The work is animal and in vitro only, published in Cytokine, with no human dosing, safety or delivery data for the combination.

From the source

Combinatorial therapy of LL-37 and ADSCs accelerates diabetic wound repair by orchestrating NRROS-mediated crosstalk between TGF-β/SMAD and hippo/TEAD1 axes

Cytokine · 2026 Nov · Wei L, Wang L, Zhong F et al.